

## 6 Literaturverzeichnis

---

- <sup>1</sup> Mutschler, E.; Geisslinger, G.; Kroemer, H. K.; Schäfer-Korting, M.: *Arzneimittelwirkungen, Lehrbuch der Pharmakologie und Toxikologie*, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, **8. Auflage**, (2001)
- <sup>2</sup> World Health Report 1997 (WHO, Geneva)
- <sup>3</sup> Blume-Jensen, P.; Hunter, T.: *Oncogenic kinase Signaling*, *Nature*, **411**, 355-365, (2001)
- <sup>4</sup> Artaega, C. L.: *The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia*, *J. Clin. Oncol.*, **19/15**, 32S-40S, (2001)
- <sup>5</sup> Ciardiello, F.; Caputo, R.; Bianco, R.; Vincenzo, D.; Pomatico, G.; De Placido, S.; Bianco, R. A.; Tortora, G.: *Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor*, *Clin. Cancer Res.*, **6**, 2053-2063, (2000)
- <sup>6</sup> Yarden, Y.; Ullrich, A.: *Growth Factor Receptor Tyrosine Kinases*, *Annu. Rev. Biochem.*, **57**, 443-478, (1988)
- <sup>7</sup> Schlessinger, J.; Ullrich, A.: *Growth Factor Signaling by Receptor Tyrosine Kinases*, *Neuron*, **9**, 383-391, (1992)
- <sup>8</sup> Harris, A. L.: *EGFR signal transduction 2001*, *Signal*, **2/3**, Poster-Beilage, (2001)
- <sup>9</sup> Raymond, E.; Faivre, S.; Armand, J. P.: *Epidermal Growth Receptor Tyrosine Kinase as a Target for Anticancer Therapy*, *Drugs*, **60/1**, 15-23, (2000)
- <sup>10</sup> Folkman, J.: *Angiogenesis in cancer, vascular, rheumatoid and other disease*, *Nat. Med.*, **1**, 27-31, (1995)
- <sup>11</sup> Folkman, J.: *Tumor angiogenesis: therapeutic implications*, *New Engl. J. Med.*, **285**, 1182-1186, (1971)
- <sup>12</sup> Liekens, S.; De Clercq, E.; Neyts, J.: *Angiogenesis: regulators and clinical applications*, *Biochem. Pharmacol.*, **61**, 253-270, (2001)
- <sup>13</sup> Zeng, H.; Sanyal, S.; Muljopadhyay, D.: *Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively*, *J. Biol. Chem.*, **276**, 32714-32719, (2001)

- 
- <sup>14</sup> Liu, M. H. et al.: *Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery*, Ann. Thorac. Surg., **73**, 819-824, (2002)
- <sup>15</sup> Ortega, S.; et al.; *Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2*, Proc. Natl. Acad. Sci. USA, **95**, 5672-5677, (1998)
- <sup>16</sup> Minchenko, A.; Bauer, T.; Salceda, S.; Caro, J.: *Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro*, Lab. Invest., **71**, 374-379, (1994)
- <sup>17</sup> Shima, D. T.; Adamis, A. P.; Ferrara, N.; Yeo, K. T.; Allende, R.; Folkman, J.; D'Amore, P. A.: *Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen*, Mol. Med., **1**, 182-193, (1995)
- <sup>18</sup> Marme, D.: *Tumor angiogenesis: the pivotal role of vascular endothelial growth factor*, World J. Urol., **14**, 166-174, (1996)
- <sup>19</sup> Senger, D. R.; Galli, S. J.; Dvorak, A. M.; Peruzzi, C. A.; Harvey, V. S.; Dvorak, H. F.: *Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid*, Sci., **219**, 983-985, (1983)
- <sup>20</sup> Bussolino, A. G.; Matonvani, A.; Persico, G.: *Molecular mechanisms of blood vessel formation*, TIBS, **22**, 251-256, (1997)
- <sup>21</sup> Vicenti, V.; Cassano, C.; Rocchi, M.; Persico, G.: *Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3*, Circ., **93**, 1493-1495, (1996)
- <sup>22</sup> Houck, K. A.; Ferrara, N.; Winer, J.; Cachianes, G.; Li, B.; Leung, D.W.: *The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA*, Mol. Endocrinol., **5**, 1806-1814, (1991)
- <sup>23</sup> Tischer, E.; Mitchell, R.; Hartmann, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J. C.; Abraham, J. A.: *The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing*, J. Biol. Chem., **266**, 11947-11954, (1991)
- <sup>24</sup> Gospodarowicz, D.; Abraham, J. A.; Shilling, J.: *Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells*, Proc. Natl. Acad. Sci. USA, **86**, 7311-7315, (1989)

- 
- <sup>25</sup> Conolly, D. T.; Olander, J. V.; Heuvelman, D. M.; Nelson, R.; Monsell, R.; Siegel, N.; Haymore, N.; Leimgruber, R.; Feger, J.: *Tumor vascular permeability factor: Isolation from U937 cells*, J. Biol. Chem., **265**, 20017-20024, (1989)
- <sup>26</sup> Ferrara, N.; Henzel, W. J.: *Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells*, Biochem. Biophys. Res. Commun., **161**, 851-858, (1989)
- <sup>27</sup> Olofsson, B.; Pajusola, K.; Kaipainen, A.; von Euler, G.; Joukov, V.; Saksela, O.; Orpana, A.; Petterson, R. F.; Alitalo, K.; Eriksson, U.: *Vascular endothelial growth factor B, a novel growth factor for endothelial cells*, Proc. Natl. Acad. Sci. USA, **93**, 2576-2581, (1996)
- <sup>28</sup> Achen, M. G.; Jeltsch, M.; Kukk, E.; Makinen, T.; Vitali, A.; Wilks, A. F.; Alitalo, K.; Stackner, S. A.: *Vascular endothelial growth factor-D is a ligand for the tyrosine kinases VEGFR-2 and VEGFR-3*, Proc. Natl. Acad. Sci. USA, **95**, 548-553, (1998)
- <sup>29</sup> Yamada, Y.; Nezu, J.; Shimane, M.; Hirata, Y.: *Molecular cloning of a novel vascular endothelial growth factor, VEGF-D*, Genomics, **42**, 483-488, (1997)
- <sup>30</sup> Joukov, V.; Sorsa, T.; Kumar, V.; Jeltsch, M. M.; Claesson-Welsh, L.; Cao, Y.; Saksela, O.; Kalkkinen, N.; Alitalo, K.: *Proteolytic processing regulates receptor specificity and activity of VEGF-C*, EMBO J., **16**, 3898-3911, (1997)
- <sup>31</sup> Lyttle, D. J.; Fraser, K. M.; Fleming, S. B.; Mercer, A. A.; Robinson, A. J.: *Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus*, J. Virol., **86**, 84-92, (1994)
- <sup>32</sup> Meyer, M.; Clauss, M.; Lepple-Wienhues, A.; Waltenberger, J.; Augustin, H. G.; Ziche, M.; Lanz, C.; Büttner, M.; Rziha, H. J.; Dehio, C.: *A novel vascular endothelial growth factor encoded by orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 but not VEGFR-1 receptor tyrosine kinases*, EMBO J., **18**, 363-374, (1999)
- <sup>33</sup> Cao, Y.; Yi, W. R.; Qi, P.; Rosin, A.: *Placenta growth factor: identification and characterization of a novel isoform generated by alternative splicing*, Biochem. Biophys. Res. Commun., **235**, 493-498, (1997)
- <sup>34</sup> Forstreuter, F.: *Effekte des Angiogenesefaktors VEGF (vascular endothelial growth factor) an Glioma- und Mikrogliazellen*, Dissertation, Christian-Albrechts-Universität Kiel, (2001)

- 
- <sup>35</sup> Marme, D.: *Tumorangiogenese: Molekulare Fakten und therapeutische Möglichkeiten*, *Der Chirurg*, **70**, 31-35, (1999)
- <sup>36</sup> Veikkola, T.; Jussila, L.; Makinen, T.; et al.: *Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice*, *EMBO J.*, **20**, 1223-1231, (2001)
- <sup>37</sup> deVries, C.; Escobedo, J. A.; Ueno, H.; Houck, K. A.; Ferrara, N.; Williams, L. T.: *The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor*, *Sci.*, **255**, 989-991, (1992)
- <sup>38</sup> Terman, B. J.; Carrion, M. E.; Kovacs, E.; Rasmussen, B. A.; Eddy, R. L.; Shows, T. B.: *Identification of a new endothelial cell growth factor receptor tyrosine kinase*, *Oncogene*, **6**, 519-524, (1991)
- <sup>39</sup> Shibuya, M.; Yamaguchi, S.; Yamane, A.; Ikeda, T.; Tojo, A.; Matsushime, H.; Sato, M.: *Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family*, *Oncogene*, **8**, 519-527, (1990)
- <sup>40</sup> Matthews, W.; Jordan, C. T.; Gavin, M.; Jenkins, N. A.; Copeland, N. G.; Limischka, I. R.: *A receptor tyrosine kinase cDNA isolated from a population of enriched primitive haematopoietic cells and exhibiting close genetic linkage to c-kit*, *Proc. Natl. Acad. Sci. USA*, **88**, 9026-9030, (1991)
- <sup>41</sup> Vaisman, N.; Gospodarowicz, D.; Neufeld, G.: *Characterization of the receptors for vascular endothelial growth factor*, *J. Biol. Chem.*, **265**, 19461-19469, (1990)
- <sup>42</sup> Ploüet, J.; Moukadir, H. J.: *Characterization of the receptors to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells*, *J. Biol. Chem.*, **265**, 22071-22075
- <sup>43</sup> Ferrara, N.: *Vascular endothelial growth factor*, *Eur. J. Cancer*, **32A**, 2413-2422, (1996)
- <sup>44</sup> Sawano, A.; Takahashi, T.; Yamaguchi, S.; Aonuma, T.; Shibuya, M.: *Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor (PlGF), which is related to vascular endothelial growth factor (VEGF)*, *Cell Growth, Diff.*, **7**, 213-221, (1996)
- <sup>45</sup> Olofsson, B.; Korpelainen, E.; Mandriota, S.; Pepper, M. S.; Aase, K.; Jeltsch, M. M.; Shibuya, M.; Alitalo, K.; Eriksson, U.: *VEGF-B binds VEGFR-1 and regulates plasminogen activator activity in endothelial cells*, *Proc. Natl. Acad. Sci. USA*, **95**, 11709-11714, (1998)

- 
- <sup>46</sup> Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H. A.; Mantovani A.; Marme, D.: *Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF-receptor Flt-1*, *Blood*, **87**, 3336-3343, (1996)
- <sup>47</sup> Gabrilovich, D. I.; Chen, H. L.; Girgis, K. R.; et al.: *Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells*, *Nat. Med.*, **2**, 1096-1103, (1996)
- <sup>48</sup> Hanks, S. K.; Quinn, A. M.; Hunter, T.: *The protein kinase family: conserved features and deduced phylogeny of the catalytic domains*, *Sci.*, **241**, 42-52, (1988)
- <sup>49</sup> Pederson, M. W.; Poulsen, H. S.: *Epidermal Growth Factor Receptor in Cancer Therapy*, *Sci. Med.*, 32-43, (2002)
- <sup>50</sup> Wells, A.: *Tumor invasion: role of growth factor-induced cell motility*, *Adv. Cancer Res.*, **78**, 31-101, (2000)
- <sup>51</sup> Hazan, R. B.; Norton, L.: *The EGFR modulates the interaction of E-Cadherin with the actin-skeleton*, *J. Biol. Chem.*, **273**, 9078-9084, (1998)
- <sup>52</sup> Damstrup, L.; Rude Voldborg, B.; Spang-Thomsen, M.; Brunner, N.; Poulsen, H. S.: *In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor*, *Br. J. Cancer*, **78**, 631-640, (1998)
- <sup>53</sup> Giordano, A.; Rustum, Y. M.; Wenner, C. E.: *Molecular Targets for Diagnosis and Therapy: Tumor Suppressor Genes and Cell Cycle Progression in Cancer*, *J. Cell. Biochem.*, **70**, 1-7, (1998)
- <sup>54</sup> Gibson, S.; Tu, S.; Oyer, R.; Anderson, S. M.; Johnson, G. L.: *Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis*, *J. Biol. Chem.*, **274**, 17612-17618, (1999)
- <sup>55</sup> De Jong, J. S.; van Diest, P. J.; van der Valk, P.; Baak, J. P. A.: *Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis*, *J. Pathol.*, **184/1**, 53-57, (1998)
- <sup>56</sup> Salomon, D. S.; Brandt, R.; Ciardello, F.; Normanno, N.: *Epidermal growth factor-related peptides and their receptors in human malignancies*, *Crit. Rev. Oncol. Hermatol.*, **19/3**, 183-232, (1995)
- <sup>57</sup> Buchdunger, E.; O'Reilly, T.; Woods-Cock, K.; Furet, P.; Traxler, P.: *PKI 166 modulates proliferation, apoptosis and tumor growth of erbB1/2 overexpressing cells*, *Proc. Am. Assoc. Cancer Res.*, **41**, 481 Abs. 3070, (2000)

- 
- <sup>58</sup> Dullea, R. G.; Barbacci, E. G.; Miller, P. E.; Moyer, J. D.: *Induction of apoptosis by CP 358,774, an inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with cisplatin (CDDP)*, Proc. Am. Assoc. Cancer Res., **41**, 401 Abs. 2550, (2000)
- <sup>59</sup> Salomon, D.; Gullick, W.: *The erbB family of receptors and their ligands: multiple targets for therapy*, Signal, **2/3**, 4-11, (2001)
- <sup>60</sup> Riese II., D. J.; Stern, D. F.: *Specificity within the EGF family/ErbB receptor family signaling network*, BioEssays, **20**, 41-48, (1998)
- <sup>61</sup> Duschl, A.: *Rezeptortyrosinkinasen*, [www.natur.sbg.ac.at/arnulf/biochem/%signal/VL%20Signal%203.pdf](http://www.natur.sbg.ac.at/arnulf/biochem/%signal/VL%20Signal%203.pdf)
- <sup>62</sup> Salomon, D.; Gullick, W.: *The erbB family of receptors and their ligands: multiple targets for therapy*, Signal, **2/3**, 4-11, (2002)
- <sup>63</sup> McInnes, C.; Sykes, B. D.: *Growth factor receptors: Structure, mechanism and drug discovery*, Biopolymers, **43/3**, 339-366, (1997)
- <sup>64</sup> Prenzel, N.; Fischer, O. M.; Streit, S.; Hart, S.; Ullrich, A.: *The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification*, Endocr. Rel. Cancer, **8**, 11-31, (2001)
- <sup>65</sup> Ullrich, A.; Coussens, L.; Hayflick, J. S.; Dull, T. J.; Gray, A.; Tam, A.; Lee, J.; Yarden, Y.; Lebermann, T.; Schlessinger, J.; Downyard, J.; Bye, J.; Whittle, N.; Waterfield, M.; Seeburg, P.: *Human epidermal growth factor receptor cDNA sequenz and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells*, Nature, **309**, 418-425, (1984)
- <sup>66</sup> Downyard, J.; Yarden, Y.; Mayers, E.; Scrace, G.; Totty, N.; Stockwell, P.; Ullrich, A.; Schlessinger, J.; Waterfield, M. D.: *Close similarity of epidermal growth factor receptor and v-erbB oncogene protein sequences*, Nature, **307**, 521-527, (1984)
- <sup>67</sup> Hong, W. K.; Ullrich, A.: *The role of EGFR in tumor growth*, Oncol. Biother., **1/1**, 2-6, (2000)
- <sup>68</sup> [www.cellsignal.com](http://www.cellsignal.com)
- <sup>69</sup> Bonni, A.; Brunet, A.; West, A. E.; Datta, S. R.; Takasu, M. A.; Greenberg, M. E.: *Cell survival promoted by Ras-MAAPK signaling pathway by transcription-dependent and -independent mechanisms*, Sci., **286**, 1358-1362, (1999)
- <sup>70</sup> Datta, S. R.; Brunet, A.; Greenberg, M. E.: *Cellular survival: a play in three akts*, Genes Dev., **13/22**, 2905-2927, (1999)

- 
- <sup>71</sup> Gross, A.; McDonnell, J. M.; Korsmeyer, S. J.: *Bcl-2 family members and the mitochondria in apoptosis*, Genes Dev., **13/15**, 1899-1911, (1999)
- <sup>72</sup> Cobb, M. H.: *MAP kinase pathways*, Prog. Biophys. Mol. Biol., **71/3-4**, 479-500, (1999)
- <sup>73</sup> Lewis, T. S.; Shapiro, P. S.; Ahn, N. G.: *Signal transduction through MAP kinase cascades*, Adv. Cancer Res., **74**, 49-139, (1998)
- <sup>74</sup> Adjei, A. A.: *Blocking oncogenic ras signaling for cancer therapy*, J. Natl. Cancer Inst., **93/14**, 1062-1074, (1994)
- <sup>75</sup> Frödin, M.; Gammelroft, S.: *Role and regulation of 90kDa ribosomal S6 kinase (RSK) in signal transduction*, Mol. Cell. Endocrinol., **151**, 65-77, (1999)
- <sup>76</sup> Kaiser, A.: *Transkriptionsfaktoren*, DAZ, **139/13**, 47-51, (1999)
- <sup>77</sup> Deak, K. M.; Clifton, A. D.; Lucocq, L. M.; Alessi, D. R.: *Mitogen- and stress-activated protein kinase-1 (MSK-1) is directly activated by MAPK and SAPK2/p38, and may mediate reactivation of CREB*, EMBO J., **17/15**, 4426-4441, (1998)
- <sup>78</sup> Lenferink, A. E.; Pinkas-Kramarski, R.; Van de Poll, M. L.; Van Vugt, M. J.; Klapper, L. N.; Tzahar, E.; Waterman, H.; Sela, M.; Van Zoelen, E. J.; Yarden, Y.: *Differential endocytic routing of homo- and heterodimeric ErbB tyrosine kinases confers signaling*, EMBO J., **17**, 3385-3397, (1998)
- <sup>79</sup> Jefferies, M. B. J.; Fumagalli, S.; Dennis, P. B.; Reinhard, C.; Pearson, R. B.; Thomas, G.: *Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70S6*, EMBO J., **16**, 3693-3704. (1997)
- <sup>80</sup> Franke, T. F.; Cantley, L. C.: *A bad kinase makes good*, Nature, **390**, 116-117, (1997)
- <sup>81</sup> Budihardjo, I.; Oliver, H.; Lutter, M.; Luo, X.; Wang, X.: *Biochemical pathways of caspase activation during apoptosis*, Annu. Rev. Cell. Dev. Biol., **15**, 269-290, (1999)
- <sup>82</sup> Van der Geer, P.; Hunter, T.; Lindberg, R. A.: *Receptor Protein-Tyrosine Kinases and their Signal Transduction Pathways*, Annu. Rev. Cell Biol., **10**, 251-337, (1994)
- <sup>83</sup> Schultz, C.; Dinkel, C.: *Phosphatidylinositol: Informationsträger der anderen Art*, Nachr. Chem., **50/5**, 590-595, (2002)
- <sup>84</sup> Fong, T. A. T.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G.: *SU5416*

- is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vasculatization and growth of multiple tumor types, Cancer Res.*, **59**, 99-106, (1999)
- <sup>85</sup> Kuenen, B. C.; et al: *Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors, J. Clin. Oncol.*, **20**, 1657-1667, (2002)
- <sup>86</sup> Laird, A. D.; Vaykoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A. T.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon, G.; Cherrington, J. M.: *SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors, Cancer Res.*, **60**, 4152-4160, (2000)
- <sup>87</sup> Britten, C.; Rosen, L.; Kabbinavar, F.; Rosen P.; Mulay, M.; Hernandez, L.: *Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers, Proc. ASCO*, **21**, 28b, (2002)
- <sup>88</sup> Kuenen, B.; Ruijter, R.; Hoekman, K.; Scigalla, P.; Giaccone, G.; Pinedo, H.: *Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies, Proc. ASCO*, **21**, 110a, (2002)
- <sup>89</sup> Rosen, L. S.; Rosen, P. J.; Kabbinavar, F.; et al.: *Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies, 37th Annu. ASCO Meet., San Francisco, CA*, 383a, (2000)
- <sup>90</sup> Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukuda, J. Y.; Chu, J. Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T. C.; Tang, F.; Wei, J.; Tang, C.: *Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-Diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase, J. Med. Chem.*, **46**, 1116-1119, (2003)
- <sup>91</sup> Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; et al.: *PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res.*, **60**, 2178-2189, (2000)



- 
- <sup>92</sup> Dreves, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Müller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marme, D.: *Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model*, *Cancer Res.*, **60**, 4819-4824, (2000)
- <sup>93</sup> Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O.: *Novel 4-Anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors*, *J. Med. Chem.*, **45**, 1300-1312, (2002)
- <sup>94</sup> Dreves, J.; Esser, N.; Marme, D.: *Effect of ZD6474, a receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma*, *Proc. AACR*, **43**, 1082, (2002)
- <sup>95</sup> Ciardiello, F.; Caputo, R.; Damiano, V.; et al.: *Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase*, *Proc. AACR 93<sup>rd</sup> Annu. Meet.*, San Francisco, CA, 5348a, (2002)
- <sup>96</sup> Basse, R.; Hurwitz, H.; Barge, A.; Davis, I.; DeBoer, R.; Holden, S.; McArthur, G.; McKinley, M.; Nairn, K.; Persky, M.; Rosenthal, M.; Swaisland, H.; Eckhardt, G.: *Phase I pharmacokinetic and biological study of the angiogenesis inhibitor ZD6474, in patients with solid tumors*, *Proc. AACR*, **20**, 100a, (2001)
- <sup>97</sup> Onoda, T.; Iinuma, H.; Sasaki, Y.; Hamade, M.; Isshiki, K.; Naganawa, H.; Takeuchi, T.: *Isolation of a novel tyrosine kinase inhibitor, Lavendustin A, from Streptomyces griseolavendus*, *J. Nat. Prod.*, **42/6**, 1252-1257, (1989)
- <sup>98</sup> Nussbaumer, P.; Winiski, A. P.; Cammisuli, S.; Hiestand, P.; Weckbecker, G.; Stütz, A.: *Novel antiproliferative agents derived from Lavendustin A*, *J. Med. Chem.*, **37**, 4079-4084, (1994)
- <sup>99</sup> Pollack, V.; Savage, D. M.; Baker, D. A.; et al.: *Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP 358,774 dynamics of receptor inhibition in situ and antitumour effects on athnic mice*, *J. Pharmacol. Exp. Ther.*, **291/2**, 739-748, (1999)

- 
- <sup>100</sup>Morin, M. J.: *From oncogene to a drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents*, *Oncogene*, **19**, 6574-6583, (2000)
- <sup>101</sup>Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchiya, H.; Takahyshi, Y.; Masuma, R.: *A new alkaloid AM-2282 of Streptomyces origin: taxonomy, fermentation, isolation and preliminary characterisation*, *J. Antibiot.*, **30**, 706-708, (1977)
- <sup>102</sup>Omura, S.; Sasaki, Y.; Iwai, Y.; Takeshimi, H.: *Staurosporine, a potentially important gift from a microorganism*, *J. Antibiot.*, **48/7**, 535-548, (1995)
- <sup>103</sup>Tamaoki, T.; Nomato, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F.: *Staurosporine, a potent inhibitor of phospholipid/Ca<sup>2+</sup> dependent protein kinase*, *Biochem. Biophys. Res. Commun.*, **135**, 397-402, (1986)
- <sup>104</sup>Link, J. T.; Raghavan, S.; Gallant, M.; Danishefsky, S. J.; Chou, T. C.; Ballas, L. M.: *Staurosporine and ent-Staurosporine: The first total syntheses, prospects for a regioselective approach, and activity profiles*, *J. Am. Chem. Soc.*, **118**, 2825-2842, (1996)
- <sup>105</sup>Wood, J. L.; Stoltz, B. M.; Goodman, S. N.: *Total synthesis of (+)-RK-286c, (+)-MLR-52, (+)-Staurosporine, and (+)-K252a*, *J. Am. Chem. Soc.*, **118/43**, 10656-10657, (1996)
- <sup>106</sup>Traxler, P. M.: *Protein tyrosine kinase inhibitors in cancer treatment*, *Exp. Opin. Ther. Pat.*, **7/6**, 571-588, (1997)
- <sup>107</sup>Brätter, S. A.: *Kronenether-verwandte Verbindungen mit 4-Pyron-Teilstrukturen: Synthesen, Reaktionsverhalten sowie Ringtransformationen mit der 4-Pyron-Untereinheit*, Dissertation, Freie Universität Berlin, (1999)
- <sup>108</sup>Barton, D. H. R.; Brown, B. D.; Ridley, D. D.; Widdowson, D. A.; Keys, A. J.; Leaver, J.: *J. Chem. Soc., Perkin Trans.I*, 2069, (1975)
- <sup>109</sup>A. Gescher: *Analogs of Staurosporine: potential anticancer drugs?*, *Gen. Pharmacol.*, **31/5**, 721-728, (1998)
- <sup>110</sup>Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J.: *Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors*, *Sci.*, **276**, 955-960, (1997)
- <sup>111</sup>Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C.: *Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine*

- kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases*, J. Med. Chem., **41**, 2588-2603, (1989)
- <sup>112</sup>Attenburrow, J.; Elks, J.; Elliott, D. F.; Hems, B. A.; Harris, J. O.; Brodrick, C. I.: *Experiments relating to the synthesis of Patulin. Part I. A study of hydrogenated  $\gamma$ -Pyrone*s, J. Chem. Soc., **2**, 571-577, (1945)
- <sup>113</sup>Ross, S. D.; Coburn, E. R.; Finkelstein, M.: Some reactions of nitrate esters in acetic acid containing sulfuric acid, J. Org. Chem., **33**, 585-587, (1968)
- <sup>114</sup>Fatiadi, A. J.: *Active Manganese dioxide oxidation in organic chemistry-Part I*, Synth., **2**, 65-104, (1976)
- <sup>115</sup>Goldman, I. M.: *Observation of a large isotope effect in the manganese dioxide oxidation of benzyl alcohol*, J. Org. Chem., **34/11**, 3289-3295, (1969)
- <sup>116</sup>Baeyer, A.: *Action of dimethyl sulphate on dimethylpyrone*, Ber. Dtsch. Chem. Ges., **43**, 2337-2343, (1910)
- <sup>117</sup>Heyns, K.; Vogelsang, G.: *Über  $\gamma$ -Pyrone und  $\gamma$ -Pyridone, II. Mitteil.: Darstellung und Eigenschaften einiger substituierter  $\gamma$ -Pyridone*, Chem. Ber., **9**, 1377-1384, (1954)
- <sup>118</sup>Morton, H. E.; Kocholaty, W.; Junowicz-Kocholaty, R.; Kelner, A.: *Toxicity and antibiotic activity of koji acid by Aspergilluts luteo-virescens*, J. Bacteriol., **50**, 579-584, (1945)
- <sup>119</sup>Yabuta, T.: *A new organic acid (koji acid) formed by Aspergillus oryzae*, J. Chem. Soc. Jap., **37**, 1185-1233, (1916)
- <sup>120</sup>Yabuta, T.: *Constitution of koji acid, a  $\gamma$ -pyrone derivative formed by Aspergillus oryzae from carbohydrates*, J. Chem. Soc., **125**, 575-587, (1924)
- <sup>121</sup>Challenger, F.; Klein, L.; Walker K. T.: *Formation of koji acid from sugars by Aspergillus oryzae*, J. Chem. Soc., **16**, 1462-1467, (1931)
- <sup>122</sup>Maurer, K.: *Conversion of simple sugars into  $\gamma$ -pyrone derivatives and the preparation of further unsaturated anhydrosugars. III.*, Ber., **63B**, 25-34, (1930)
- <sup>123</sup>Maurer, K.: *The hydrogenation of kojic acid and its relation to the dismutation products of the sugars*, Ber., **64B**, 2358-2360, (1931)
- <sup>124</sup>Balaban, A. T.; Schroth, W.; Fischer, G.: *Pyrylium salts. I. Syntheses*, Adv. Heterocycl. Chem., **10**, 241, (1969)
- <sup>125</sup>Armit, J. W.; Nolan, T. J.: *Derivatives of Koji acid*, J. Chem. Soc., 3023-3031, (1931)

- <sup>126</sup>Prey, V.: *Die Spaltung von Phenoläthern mit Pyridinhydrochlorid*, Ber., **74B**, 1219-1225, (1941)
- <sup>127</sup>[www.dtp.nci.nih.gov](http://www.dtp.nci.nih.gov)
- <sup>128</sup>Ignar-Teowbridge, D. M.; Nelson, K.; Bidwell, M. C.; Curtis, S. W.; Washburn, T. F.; McLachlan, J. A.; Korach, K. S.: *Coupling of dual signalling pathways: Epidermal growth factor action involves the estrogen receptor*, Proc. Natl. Acad. Sci., **89**, 4658-4662, (1992)
- <sup>129</sup>Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O.: *Novel 4-Anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors*, J. Med. Chem, **45**, 1300-1312, (2002)
- <sup>130</sup>Morin, M. J.: *From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents*, Oncogene, **19**, 6574-6583, (2000)
- <sup>131</sup>Traxler, P.; Furet, P.: *Strategies toward the design of novel and selective protein tyrosine kinase inhibitors*, Pharmacol. Ther., **82 (2-3)**, 195-206, (1999)
- <sup>132</sup>Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N.: *4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-Receptor Tyrosine Kinase*, J. Med. Chem., **39**, 2285-2292, (1996)
- <sup>133</sup>Traxler, P.; Green, J.; Mett, H.; Sequin, U.; Furet, P.: *Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-Phenyl-4(1H)-quinolones*, J. Med. Chem., **42**, 1018-1026, (1999)
- <sup>134</sup>Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Hollis Showalter, H. D.; Denny, W. A.: *Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding*, J. Med. Chem., **40**, 1519-1529, (1997)
- <sup>135</sup>Albuschat, R.: *Neue EGFR-Tyrosinkinase-Inhibitoren mit Salicyl- oder Chinazolin-Teilstrukturen*, Dissertation, Freie Universität Berlin, (2003)
- <sup>136</sup>Hou, T.; Zhu, L.; Chen, L.; Xu, X.: *Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies*, J. Chem. Inf. Comput. Sci., **43**, 273-287, (2003)

- <sup>137</sup>Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W.: *Tyrosine kinase inhibitors 5. Synthesis and structure-relationships for 4-[(Phenylmethyl)-amino]- and 4-(Phenylamino)-quinazolines as potent adenosine 5'-Triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor*, J. Med. Chem., **38/18**, 3482-3487, (1995)
- <sup>138</sup>Wissner, A.; Berger, D. M.; Boschelli, D. H.; Brawner Floyd, M.; Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslakis, E.; Wang, Y. F.; Wu, B.; Ye, F.; Zhang, N.: *4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-Anilino-6,7-dialkoxyquinazoline inhibitors*, J. Med. Chem., **43**, 3244-3256, (2000)
- <sup>139</sup>Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C.: (*Publikation in Vorbereitung*)
- <sup>140</sup>Bridges, A. J.; Zhou, H.; Cody, D.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A.: *Tyrosine kinase inhibitors 8. An unusually steep structure activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor*, J. Med. Chem., **39/1**, 267-276, (1996)
- <sup>141</sup>N. N.: *Iressa™*, Drugs of the Future, **27/4**, 339-345, (2002)
- <sup>142</sup>N. N.: *Erlotinib hydrochloride*, Drugs of the Future, **27/10**, 923-934, (2002)
- <sup>143</sup>Woodburn, J. R.: *The epidermal growth factor receptor and its inhibition in cancer therapy*, Pharmacol. Ther., **82**, 241-250, (1999)
- <sup>144</sup>Rusnack, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R.J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K.: *The characterization of novel, dual ErbB-2/EGFR tyrosine kinase inhibitors: Potential therapy for cancer*, Cancer Res., **61**, 7196-7203, (2001)
- <sup>145</sup>Christensen, J. G.; Schreck, R. E.; Chan, E. et al.: *High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo*, Clin. Cancer Res., **7**, 4230-4238, (2001)

- <sup>146</sup>Moyer, J. D.; Barbacci, E. G.; Iwata, K. K. et al.: *Induction of apoptosis and cell cycle arrest by CP 358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase*, *Cancer Res.*, **42**, 4838-4848, (1997)
- <sup>147</sup>Onoda, T.; Isshi, K.; Takeuchi, T.; Tatsuta, K.; Umezawa, K.: *Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by Lavendustin A methylester in cultured A431 cells*, *Drugs Exp. Clin. Res.*, **16/6**, 249-253, (1990)
- <sup>148</sup>Nussbaumer, P.; Winiski, A. P.; Cammisuli, S.; Hiestand, D.; Weckbecker, G.; Stütz, A.: *Novel antiproliferative agents derived from Lavendustin A*, *J. Med. Chem.*, **37**, 4079-4084, (1994)
- <sup>149</sup>Stevenson, T. M.; Kazmierczak, F.; Leonard, N. J.: *Defined dimensional alterations in enzyme substrates. General synthetic methodology for the bent Dihydro-lin-benzopurines*, *J. Org. Chem.*, **51**, 616-620, (1986)
- <sup>150</sup>Geissler, J. F.; Traxler, P.; Regenass, U.; Murray, B. J.; Roesel, J. L.; Meyer, T.; McGlynn, E.; Storni, A.; Lydon, N. B.: *Thiazolidine-diones: Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors*, *J. Biol. Chem.*, **265**, 22255-22261, (1990)
- <sup>151</sup>Wedegartner, P. S.; Gill, G. N.: *Activation of the purified protein tyrosine kinase domain of the epidermal growth factor receptor*, *J. Biol. Chem.*, **264**, 11346-11353, (1989)
- <sup>152</sup>Yaish, P.; Gazit, A.; Golin, C.; Levitzki, A.: *Blocking of EGF-dependent cell proliferation by EGF receptor tyrosine kinase inhibitors*, *Sci.*, **242**, 933-935, (1988)
- <sup>153</sup>Nussbaumer, P.; Winiski, A. P.; Cammisuli, S.; Hiestand, D.; Weckbecker, G.; Stütz, A.: *Novel antiproliferative agents derived from Lavendustin A*, *J. Med. Chem.*, **37**, 4079-4084, (1994)
- <sup>154</sup>Albuschat, R.: *Neue EGFR-Tyrosinkinase-Inhibitoren mit Salicyl- oder Chinazolin-Teilstrukturen*, Dissertation, Freie Universität Berlin, (2003)
- <sup>155</sup>Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Hollis Showalter, H. D.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A.: *Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor*, *J. Med. Chem.*, **39**, 918-928, (1996)
- <sup>156</sup>Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Hollis Showalter, H. D.; Vincent, P. W.; Elliott, W. L.; Denny, W. A.:

- Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)chinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions*, J. Med. Chem., **43**, 1380-1397, (2000)
- <sup>157</sup>Günther, G., in *NMR-Spektroskopie*, Georg Thieme Verlag, Stuttgart, S. 371
- <sup>158</sup>Brätter, S. A.: *Kronenether-verwandte Verbindungen mit 4-Pyron-Teilstrukturen : Synthesen, Reaktionsverhalten sowie Ringtransformationen mit der 4-Pyron-Untereinheit*, Dissertation, Freie Universität Berlin, (1999)
- <sup>159</sup>Attenburrow, J.; Elks, J.; Elliott, D. F.; Hems, B. A.; Harris, J. O.; Brodrick, C. I.: *Experiments relating to the synthesis of Patulin. Part I. A study of hydrogenated  $\gamma$ -Pyrones*, J. Chem. Soc., **2**, 571-577, (1945)
- <sup>160</sup>Fantin, G.; Fogagnolo, M.; Medici, A.; Pedrini, P.: *Tetrahydropyrido[2,1-b]quinazolin-11-ones and tetrahydropyrido[1,2-a]quinazolin-6-ones via thermal cyclization of 2-substituted 4(3H)-quinazolinones*, J. Org. Chem., **58/3**, 741-743, (1993)
- <sup>161</sup>Gray, G. D.; Wickstrom, E.: *Evaluation of anchorage-independent proliferation in tumorigenic cells using the redox dye alamar blue*, BioTechniques, **21/5**, 780-782, (1996)
- <sup>162</sup>Lin, A.: (MDS Pharma Services, Taiwan R.O.C.), Mitteilung